Notice of General Meeting/Proxy Form
Released
Released
Announcement PDF
.
Emyria Limited
ACN 625 085 734
Notice of General Meeting
TIME AND DATE: Tuesday, 19 August 2025 at 3.30pm (AWST)
LOCATION:
At the offices of Stantons International, Level 2, 40 Kings
Park Road, West Perth, WA, Australia
The Notice of General Meeting should be read in its entirety. If Shareholders are in doubt
as to how to vote, they should seek advice from their accountant, solicitor or other
professional advisor prior to voting.
Should you wish to discuss any matter, please do not hesitate to contact the
Company Secretary by telephone on +61 8 6559 2800.
Shareholders are urged to attend the Meeting or vote by lodging the Proxy Form
attached to the Notice.
Emyria Limited
ACN 625 085 734
(Company)
Notice of General Meeting
Notice is given that the general meeting of Shareholders of Emyria Limited (Company) will be held at
the offices of Stantons International, Level 2, 40 Kings Park Road, West Perth, WA, Australia on
Tuesday, 19 August 2025 at 3.30pm (AWST) (Meeting).
The Directors have determined pursuant to regulation 7.11.37 of the Corporations Regulations 2001
(Cth) that the persons eligible to vote at the Meeting are those who are registered as Shareholders on
Sunday, 17 August 2025 at 3.30pm (AWST).
The Explanatory Memorandum provides additional information on matters to be considered at the
Meeting. The Explanatory Memorandum and the Proxy Form, form part of the Notice.
Terms and abbreviations used in the Notice are defined in Schedule 1.
Agenda
1.
RESOLUTIONS
Resolution 1 – Ratification of issue of UWA Shares
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
‘That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes,
Shareholders ratify the issue of 2,083,333 UWA Shares issued under Listing Rule 7.1 on the
terms and conditions in the Explanatory Memorandum.’
Resolution 2 – Ratification of issue of Tranche 1 Placement Shares
To consider and, if thought fit, to pass with or without amendment, each as a separate
ordinary resolution the following:
‘That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes,
Shareholders ratify the issue of:
(a)
71,290,790 Tranche 1 Placement Shares issued under Listing Rule 7.1; and
(b)
48,916,082 Tranche 1 Placement Shares issued under Listing Rule 7.1A,
Page 2
on the terms and conditions in the Explanatory Memorandum.’
Resolution 3 – Approval to issue Tranche 2 Placement Shares
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
‘That, pursuant to and in accordance with Listing Rule 7.1 and for all other purposes,
Shareholders approve the issue of up to 34,501,462 Tranche 2 Placement Shares, on the
terms and conditions in the Explanatory Memorandum.’
Resolution 4 – Approval to issue Placement Options
To consider and, if thought fit, to pass, with or without amendment, the following resolution as
an ordinary resolution the following:
‘That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the
Company to issue up to 51,569,445 Placement Options on the terms and conditions set out in
the Explanatory Memorandum.’
Resolution 5 – Approval to issue Director Placement Securities
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That, pursuant to and in accordance with Listing Rule 10.11 and for all other purposes,
Shareholders approve the issue of up to 11,958,333 Director Placement Shares and
3,986,111 Director Placement Options to the following Directors (or their respective
nominee/s) as follows:
(a)
up to 208,333 Director Placement Shares and 69,444 Director Placement Options to
Michael Winlo; and
(b)
up to 11,750,000 Director Placement Shares and 3,916,667Director Placement
Options to Greg Hutchinson,
on the terms and conditions in the Explanatory Memorandum.’
Resolution 6 – Approval to issue Lead Manager Options
To consider and, if thought fit, to pass, with or without amendment, the following resolution as
an ordinary resolution the following:
‘That pursuant to and in accordance with Listing Rule 7.1 and for all other purposes, approval
is given for the Company to issue up to 2,500,000 Lead Manager Options to GBA Capital on
the terms and conditions set out in the Explanatory Memorandum.’
Page 3
Resolution 7 – Approval to issue S3 Shares
To consider and, if thought fit, to pass, with or without amendment, the following resolution as
an ordinary resolution the following:
‘That pursuant to and in accordance with Listing Rule 7.1 and for all other purposes, approval
is given for the Company to issue up 6,250,000 S3 Shares to S3 Consortium on the terms and
conditions set out in the Explanatory Memorandum.’
Resolution 8 – Approval to issue S3 Options
To consider and, if thought fit, to pass, with or without amendment, the following resolution as
an ordinary resolution the following:
‘That pursuant to and in accordance with Listing Rule 7.1 and for all other purposes, approval
is given for the Company to issue up to a total of 2,083,333 S3 Options to S3 Consortium on
the terms and conditions set out in the Explanatory Memorandum.’
Voting exclusions
Pursuant to the Listing Rules, the Company will disregard any votes cast in favour of:
(a)
Resolution 1: by or on behalf of UWA, or any of their associates, or their nominees.
(b)
Resolution 2(a): by or on behalf of any person who participated in the issue of these
Tranche 1 Placement Shares, or any of their respective associates, or their nominees.
(c)
Resolution 2(b): by or on behalf of any person who participated in the issue of these
Tranche 1 Placement Shares, or any of their respective associates, or their nominees.
(d)
Resolution 3: by or on behalf of any person who is expected to participate in, or who
will obtain a material benefit as a result of, the proposed issue of the Tranche 2
Placement Shares (except a benefit solely by reason of being a Shareholder), or any
of their respective associates.
(e)
Resolution 4: by or on behalf of any person who is expected to participate in, or who
will obtain a material benefit as a result of, the proposed issue of the Placement
Options (except a benefit solely by reason of being a Shareholder), or any of their
respective associates.
(f)
Resolution 5(a): by or on behalf of Michael Winlo (or his nominee/s), and any other
person who will obtain a material benefit as a result of the issue of these Director
Placement Securities (except a benefit solely by reason of being a Shareholder), or
any of their respective associates.
(g)
Resolution 5(b): by or on behalf of Greg Hutchinson (or his nominee/s), and any
other person who will obtain a material benefit as a result of the issue of these Director
Placement Securities (except a benefit solely by reason of being a Shareholder), or
any of their respective associates.
(h)
Resolution 6: by or on behalf of GBA Capital (or its nominee/s), and any other person
who will obtain a material benefit as a result of, the proposed issue of the Lead
Page 4
Manager Options (except a benefit solely by reason of being a Shareholder), or any of
their associates.
(i)
Resolution 7: by or on behalf of S3 Consortium (or its nominee/s), and any other
person who will obtain a material benefit as a result of, the proposed issue of the S3
Shares (except a benefit solely by reason of being a Shareholder), or any of their
associates.
(j)
Resolution 8: by or on behalf of S3 Consortium (or its nominee/s), and any other
person who will obtain a material benefit as a result of, the proposed issue of the S3
Options (except a benefit solely by reason of being a Shareholder), or any of their
associates.
The above voting exclusion does not apply to a vote cast in favour of the relevant Resolution
by:
(a)
a person as proxy or attorney for a person who is entitled to vote, in accordance with
directions given to the proxy or attorney to vote on the Resolution in that way;
(b)
the Chair as proxy or attorney for a person who is entitled to vote, in accordance with
a direction given to the Chair to vote on the Resolution as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on
behalf of a beneficiary provided the following conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary
is not excluded from voting, and is not an associate of a person excluded from
voting, on the Resolution; and
(ii)
the holder votes on the Resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
BY ORDER OF THE BOARD
Susan Park
Company Secretary
Emyria Limited
Dated: 18 July 2025
Page 5
Emyria Limited
ACN 625 085 734
(Company)
Explanatory Memorandum
2.
Introduction
The Explanatory Memorandum has been prepared for the information of Shareholders in
connection with the business to be conducted at the Meeting to be held at the offices of
Stantons International, Level 2, 40 Kings Park Road, West Perth, WA, Australia on Tuesday,
19 August 2025 at 3.30pm (AWST) (Meeting).
The Explanatory Memorandum forms part of the Notice which should be read in its entirety.
The Explanatory Memorandum contains the terms and conditions on which the Resolutions
will be voted.
The Explanatory Memorandum includes the following information to assist Shareholders in
deciding how to vote on the Resolutions:
Section 2
Introduction
Section 3
Voting and attendance information
Section 4
Background to the Placement
Section 5
Resolution 1 – Ratification of issue of UWA Shares
Section 6
Resolution 2 – Ratification of issue of Tranche 1 Placement Shares
Section 7
Resolution 3 – Approval to issue Tranche 2 Placement Shares
Section 8
Resolution 4 – Approval to issue Placement Options
Section 9
Resolution 5 – Approval to issue Director Placement Securities
Section 10
Resolution 6 – Approval to issue Lead Manager Options
Section 11
Resolution 7 – Approval to issue S3 Shares
Section 12
Resolution 8 – Approval to issue S3 Options
Schedule 1
Definitions
Schedule 2
Terms and Conditions of Placement Options, Lead Manager Options,
Director Placement Options and S3 Options.
A Proxy Form is located at the end of the Explanatory Memorandum.
3.
Voting and attendance information
Shareholders should read the Notice including the Explanatory Memorandum carefully before
deciding how to vote on the Resolutions.
Page 6
3.1
Voting in person
To vote in person, attend the Meeting on the date and at the place set out above.
3.2
Voting by proxy
A Proxy Form is attached to the Notice. This is to be used by Shareholders if they wish to
appoint a representative (a 'proxy') to vote in their place. All Shareholders are encouraged to
vote by completing and returning the Proxy Form to the Company in accordance with the
instructions thereon. Lodgement of a Proxy Form will not preclude a Shareholder from
attending and voting at the Meeting in person.
Please note that:
(i)
a member of the Company entitled to attend and vote at the Meeting is entitled to
appoint a proxy;
(ii)
a proxy need not be a member of the Company; and
(iii)
a member of the Company entitled to cast two or more votes may appoint two proxies
and may specify the proportion or number of votes each proxy is appointed to exercise,
but where the proportion or number is not specified, each proxy may exercise half of
the votes.
The enclosed Proxy Form provides further details on appointing proxies and
lodging Proxy Forms.
Section 250BB(1) of the Corporations Act provides that an appointment of a proxy may specify
the way the proxy is to vote on a particular resolution and, if it does:
(i)
the proxy need not vote on a show of hands, but if the proxy does so, the proxy must
vote that way (i.e. as directed);
(ii)
if the proxy has 2 or more appointments that specify different ways to vote on the
resolution – the proxy must not vote on a show of hands;
(iii)
if the proxy is the Chair of the meeting at which the resolution is voted on – the proxy
must vote on a poll, and must vote that way (i.e. as directed); and
(iv)
if the proxy is not the Chair – the proxy need not vote on the poll, but if the proxy does
so, the proxy must vote that way (i.e. as directed).
Section 250BC of the Corporations Act provides that, if:
(i)
an appointment of a proxy specifies the way the proxy is to vote on a particular
resolution at a meeting of the Company's members;
(ii)
the appointed proxy is not the chair of the meeting;
(iii)
at the meeting, a poll is duly demanded on the resolution; and
(iv)
either the proxy is not recorded as attending the meeting or the proxy does not vote on
the resolution,
the Chair of the meeting is taken, before voting on the resolution closes, to have been
appointed as the proxy for the purposes of voting on the resolution at the meeting.
Page 7
3.3
Chair's voting intentions
The Chair intends to exercise all available proxies in favour of all Resolutions, unless the
Shareholder has expressly indicated a different voting intention.
3.4
Submitting questions
Shareholders may submit questions in advance of the Meeting to the Company. Questions
must be submitted by emailing the Company Secretary at info@emyria.com at least 5
Business Days prior to the Meeting.
Shareholders will also have the opportunity to submit questions during the Meeting in respect
to the formal items of business. In order to ask a question during the Meeting, please follow
the instructions from the Chair.
The Chair will attempt to respond to the questions during the Meeting. The Chair will request
prior to a Shareholder asking a question that they identify themselves (including the entity
name of their shareholding and the number of Shares they hold).
4.
Background to the Placement
On 18 June 2025, the Company announced that it had obtained firm commitments for a capital
raising of $4,000,000 (before costs) through the issue of Shares in the Company (Placement
Shares) at an issue price of $0.024 per Share (Placement). Participants in the Placement will
also receive one (1) free attaching unquoted Option for every three (3) Placement Shares
subscribed for, exercisable at $0.05 each and expiring 18 months from the date of issue
(Placement Options).
The Placement is comprised of the following tranches:
(a)
120,206,872 Placement Shares issued utilising the Company’s available placement
capacity pursuant to Listing Rules 7.1 and 7.1A (the subject of Resolution 2(a) and
Resolution 2(b)) (Tranche 1 Placement Shares);
(b)
34,501,462 Placement Shares (Tranche 2 Placement Shares) proposed to be issued
subject to Shareholder approval under Listing Rule 7.1 (the subject of Resolution 3);
(c)
51,569,445 Placement Options proposed to be issued subject to Shareholder approval
under Listing Rule 7.1 (the subject of Resolution 4); and
(d)
11,958,333 Shares (Director Placement Shares) and 3,986,111 Options (Director
Placement Options) proposed to be issued to Michael Winlo and Greg Hutchinson
(or their respective nominee/s) subject to Shareholder approval under Listing Rule
10.11 (the subject of Resolution 5(a) and Resolution 5(b)).
The Company engaged GBA Capital Group Pty Ltd as lead manager and corporate advisor to
the Placement (Lead Manager). As partial consideration for the provision of lead manager
and corporate advisory services in connection with the Placement, the Lead Manager (or its
nominees) will be issued 2,500,000 Options on the same terms as the Placement Options
Page 8
(Lead Manager Options), subject to Shareholder approval under Listing Rule 7.1 (the subject
of Resolution 6).
5.
Resolution 1 – Ratification of issue of UWA Shares
5.1
Background
On 31 October 2024, the Company announced that it had entered into an exclusive licence
agreement with the University of Western Australia (UWA) (UWA Agreement).
As consideration under the UWA Agreement, the Company issued 2,083,333 Shares (UWA
Shares) to UWA using the Company’s available placement capacity under Listing Rule 7.1 on
4 March 2025.
Resolution 1 seeks the approval of Shareholders pursuant to Listing Rule 7.4 to ratify the
issue of the UWA Shares under Listing Rules 7.1.
5.2
Summary of the UWA Agreement
A summary of the material terms and conditions of the UWA Agreement are as follows:
(a)
(Parties): the Company and UWA.
(b)
(Licence): the Company receives worldwide exclusive rights for all fields and
applications for patent titled: “ANALOGUES OF MDMA FOR MODULATING SERT,
DAT AND/OR NET ACTIVITY” (PCT/AU2022/051422).
(c)
(Consideration): the Company is required to issue Shares to the value of:
(i)
$62,500 at a deemed issue price of $0.03 (totalling 2,083,333 the subject of
this Resolution 1);
(ii)
subject to Shareholder approval, $62,500, on successful completion of preclinical in vivo efficacy experiments of the first lead compound in a rodent
model that has positive results; and
(iii)
subject to Shareholder approval, $62,500, when one or more new national
phase patent applications are first filed for a patentable invention.
The Company will also pay a royalty based on net sales by sub-licensees which will
be:
(iv)
2% of net sales if the royalty received by the Company under a valid sublicense is ≥ 6% of net sales, or if there is no sub-license; or
(v)
30% of the royalty received by the Company under a valid sub-license, if the
royalty received by the Company is < 6% of net sales, but in every event, no
less than 1% net sales.
The UWA Agreement otherwise contains terms and conditions considered standard for an
agreement of this nature.
Page 9
5.3
Listing Rules 7.1 and 7.4
Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of
Equity Securities that a listed company can issue without the approval of its shareholders over
any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that
period.
The issue of the UWA Placement Shares does not fit within any of the exceptions to Listing
Rules 7.1 and, as it has not yet been approved by Shareholders, effectively uses up part of the
Company's placement capacity under Listing Rules 7.1. This reduces the Company's capacity
to issue further Equity Securities without Shareholder approval under Listing Rule 7.1 for the
12 month period following the issue of the UWA Placement Shares.
Listing Rule 7.4 provides an exception to Listing Rules 7.1. It provides that where a company
in a general meeting ratifies the previous issue of securities made pursuant to Listing Rules
7.1 (and provided that the previous issue did not breach Listing Rules 7.1), those Equity
Securities will be deemed to have been made with shareholder approval for the purpose of
Listing Rules 7.1. The Company confirms that the issue of the UWA Shares did not breach
Listing Rule 7.1.
The effect of Shareholders passing Resolution 1 will be to allow the Company to retain the
flexibility to issue Equity Securities in the future up to the 15% placement capacity set out in
Listing Rule 7.1 without the requirement to obtain prior Shareholder approval.
If Resolution 1 is passed, 2,083,333 UWA Shares will be excluded in calculating the
Company's 15% limit in Listing Rule 7.1, effectively increasing the number of Equity Securities
it can issue without Shareholder approval over the 12 month period following the issue date.
If Resolution 1 is not passed, 2,083,333 UWA Shares will continue to be included in the
Company's 15% limit under Listing Rule 7.1, effectively decreasing the number of Equity
Securities the Company can issue or agree to issue without obtaining prior Shareholder
approval, to the extent of 2,083,333 Equity Securities for the 12 month period following the
issue of those Placement Shares.
5.4
Specific information required by Listing Rule 7.5
Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in
relation to the ratification of the issue of the UWA Placement Shares:
(a)
The UWA Shares were issued to nominees of UWA, none of which are a related party
or Material Investor.
(b)
A total of 2,083,333 UWA Shares were issued under Listing Rule 7.1.
(c)
The UWA Shares are fully paid ordinary shares in the capital of the Company and rank
equally in all respects with the Company's existing Shares on issue.
(d)
The UWA Shares were issued on 4 March 2025.
(e)
The number of UWA Shares were calculated using a deemed issue price of $0.03 each
to a value of $62,500.
Page 10
5.5
(f)
The purpose of the issue of the UWA Shares is to discharge the Company’s obligations
to pay the consideration to UWA in accordance with the UWA Agreement summarised
at Section 5.2 above. Accordingly, no funds will be raised from the issue.
(g)
A summary of the material terms and conditions of the UWA is in Section 5.2 above.
(h)
A voting exclusion statement is included in the Notice.
Additional information
Resolution 1 is an ordinary resolution.
The Board recommends that Shareholders vote in favour of Resolution 1.
6.
Resolution 2 – Ratification of issue of Tranche 1 Placement Shares
6.1
Background
The background to the Placement and the issue of the Tranche 1 Placement Shares is set out
in Section 4 above.
On 26 June 2025, the Company issued the Tranche 1 Placement Shares using the
Company’s available placement capacity as follows:
(a)
71,290,790 Tranche 1 Placement Shares under Listing Rule 7.1; and
(b)
48,916,082 Tranche 1 Placement Shares under Listing Rule 7.1A.
Resolution 2(a) and (b) seek the approval of Shareholders pursuant to Listing Rule 7.4 to ratify
the issue of the Tranche 1 Placement Shares under Listing Rules 7.1 and 7.1A respectively.
6.2
Listing Rules 7.1, 7.1A and 7.4
A summary of Listing Rule 7.1 is in Section 5.3 above.
Under Listing Rule 7.1A, an eligible entity can seek approval from its members, by way of a
special resolution passed at its annual general meeting, to increase its 15% placement
capacity under Listing Rule 7.1 by an extra 10% to 25%. The Company obtained this approval
at its annual general meeting held on 12 November 2024.
The issue of the Tranche 1 Placement Shares does not fit within any of the exceptions to
Listing Rules 7.1 and 7.1A and, as it has not yet been approved by Shareholders, effectively
uses up part of the Company's placement capacities under Listing Rules 7.1 and 10%
placement capacity under Listing Rule 7.1A. This reduces the Company's capacity to issue
further Equity Securities without Shareholder approval under those Listing Rules for the 12
month period following the issue of the Tranche 1 Placement Shares.
Listing Rule 7.4 provides an exception to Listing Rules 7.1 and 7.1A. It provides that where a
company in a general meeting ratifies the previous issue of securities made pursuant to Listing
Rules 7.1 and 7.1A (and provided that the previous issue did not breach Listing Rules 7.1 and
7.1A), those Equity Securities will be deemed to have been made with shareholder approval
for the purpose of Listing Rules 7.1 and 7.1A. The Company confirms that the issue of the
Tranche 1 Placement Shares did not breach Listing Rule 7.1 and 7.1A.
Page 11
The effect of Shareholders passing Resolution 2(a) and (b) will be to allow the Company to
retain the flexibility to issue Equity Securities in the future up to the 15% placement capacity
set out in Listing Rule 7.1 and the 10% additional placement capacity set out in Listing Rule
7.1A without the requirement to obtain prior Shareholder approval.
If Resolution 2(a) is passed, 71,290,790 Tranche 1 Placement Shares will be excluded in
calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of
Equity Securities it can issue without Shareholder approval over the 12 month period following
the issue date.
If Resolution 2(b) is passed, 48,916,082 Tranche 1 Placement Shares will be excluded in
calculating the Company's 10% limit in Listing Rule 7.1A, effectively increasing the number of
Equity Securities it can issue without Shareholder approval over the 12 month period following
the issue date.
If Resolution 2(a) is not passed, 71,290,790 Tranche 1 Placement Shares will continue to be
included in the Company's 15% limit under Listing Rule 7.1, effectively decreasing the number
of Equity Securities the Company can issue or agree to issue without obtaining prior
Shareholder approval, to the extent of 71,290,790 Equity Securities for the 12 month period
following the issue of those Placement Shares.
If Resolution 2(b) is not passed, 48,916,082 Tranche 1 Placement Shares will continue to be
included in the Company's 10% limit under Listing Rule 7.1A, effectively decreasing the
number of Equity Securities the Company can issue or agree to issue without obtaining prior
Shareholder approval, to the extent of 48,916,082 Equity Securities for the 12 month period
following the issue of those Placement Shares (and assuming the Company's approval under
Listing Rule 7.1A remains in force for this period).
6.3
Specific information required by Listing Rule 7.5
Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in
relation to the ratification of the issue of the Tranche 1 Placement Shares:
(a)
The Tranche 1 Placement Shares were issued to institutional and sophisticated
investors (Tranche 1 Placement Participants), none of whom is a related party of the
Company or a Material Investor. The Tranche 1 Placement Participants were identified
through a bookbuild process, which involved the Company and Lead Manager seeking
expressions of interest to participate in the Placement from new and existing contacts
of the Company and clients of the Lead Manager.
(b)
A total of 120,206,872 Tranche 1 Placement Shares using the Company’s available
placement capacity in the following proportions:
(i)
71,290,790 Tranche 1 Placement Shares under Listing Rule 7.1; and
(ii)
48,916,082 Tranche 1 Placement Shares under Listing Rule 7.1A.
(c)
The Tranche 1 Placement Shares are fully paid ordinary shares in the capital of the
Company and rank equally in all respects with the Company's existing Shares on issue.
(d)
The Tranche 1 Placement Shares were issued on 26 June 2025 at an issue price of
$0.024 each.
(e)
The proceeds from the Placement have been or are intended to be used:
Page 12
6.4
(i)
to support the Company’s expanded treatment programs, including those
funded under the Medibank agreement;
(ii)
for costs of the Placement; and
(iii)
for general working capital.
(f)
There are no other material terms to the agreement for the subscription of the
Tranche 1 Placement Shares.
(g)
A voting exclusion statement is included in the Notice.
Additional information
Resolution 2(a) and 2(b) are each separate ordinary resolutions and are not inter-conditional.
The Board recommends that Shareholders vote in favour of Resolution 2(a) and 2(b).
7.
Resolution 3 – Approval to issue Tranche 2 Placement Shares
7.1
Background
The Background to the Placement, including the proposed issue of the Tranche 2 Placement
Shares is set out in Section 4 above.
Resolution 3 seeks the approval of Shareholders pursuant to Listing Rule 7.1 to approve the
issue of the Tranche 2 Placement Shares.
7.2
Listing Rules 7.1
A summary of Listing Rule 7.1 is contained in Section 6.2 above.
The issue of the Tranche 2 Placement Shares does not fall within any of the exceptions to
Listing Rule 7.1 and exceeds the 15% limit in Listing Rule 7.1. It therefore requires the
approval of Shareholders under Listing Rule 7.1.
If Resolution 3 is passed, the Company will be able to proceed with the issue of the Tranche 2
Placement Shares.
If Resolution 3 is not passed, the Company will not be able to proceed with the issue of the
Tranche 2 Placement Shares and will not receive approximately $828,035 from the issue of
the Tranche 2 Placement Shares.
7.3
Specific information required by Listing Rule 7.3
Pursuant to and in accordance with Listing Rule 7.3, the following information is provided in
relation to the proposed issue of the Tranche 2 Placement Shares:
(a)
The Tranche 2 Placement Shares will be issued to institutional and sophisticated
investors (Tranche 2 Placement Participants), none of whom are a related party of
the Company or a Material Investor. The Tranche 2 Placement Participants were
identified through the same process as the Tranche 1 Placement Participants (refer to
Section 6.3(a)).
Page 13
7.4
(b)
A maximum of 34,501,462 Tranche 2 Placement Shares will be issued.
(c)
The Tranche 2 Placement Shares will be fully paid ordinary shares in the capital of the
Company and will rank equally in all respects with the Company's existing Shares on
issue.
(d)
The Tranche 2 Placement Shares will be issued no later than 3 months after the date
of the Meeting.
(e)
The Tranche 2 Placement Shares will be issued at a price of $0.024 each, being the
same issue price as the Tranche 1 Placement Shares and will raise up to
approximately $828,035 (before costs).
(f)
A summary of the intended use of funds raised from the Placement is set out in
Section 6.3(e) above.
(g)
There are no other material terms to the agreement for the subscription of the Tranche
2 Placement Shares.
(h)
A voting exclusion statement is included in the Notice.
Additional information
Resolution 3 is an ordinary resolution.
The Board recommends that Shareholders vote in favour of Resolution 3.
8.
Resolution 4 – Approval to issue Placement Options
8.1
Background
The background to the Placement and the proposed issue of the Placement Options is set out
in Section 4 above.
Resolution 4 seeks Shareholder approval pursuant to Listing Rule 7.1 to approve the issue of
the Placement Options.
8.2
Listing Rule 7.1
A summary of Listing Rule 7.1 is containe
Share your feedback
Discover